Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of
the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the …

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to …

Abstract Purpose of Review Despite significant progress, patients with metastatic prostate
cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for …

Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform
standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was …

Mechanistic target of rapamycin (mTOR) is a protein kinase that regulates cellular growth,
development, survival, and metabolism through integration of diverse extracellular and …

Abstract Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway
activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib …

Androgen deprivation therapy is administered to suppress the growth of prostate cancer
(PCa). However, some cells continue to proliferate independent of hormones, leading to the …

Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …